Login to Your Account

Pharmas move from bricks and mortar to open innovation with R&D hubs

By Marie Powers
Staff Writer

Tuesday, September 2, 2014

After a decade of consolidation that led to blended organizations, shuttered R&D facilities and the shedding of tens of thousands of jobs, big pharma is rebuilding its internal pipeline. This time, however, the footprint looks distinctly different. Instead of constructing giant silos focused on carefully defined projects, the industry is fashioning R&D hubs with flexible designs that are close to the ground floor of discovery.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription